Efficacy News and Research

RSS

Experimental malaria vaccine shows positive results among children in small Burkina Faso study

"An experimental malaria vaccine tested on children in Burkina Faso has shown 'a high level of efficacy' in protecting against the disease, a study published in" Thursday's New England Journal of Medicine said, according to Agence France-Presse.

16 Sep 2011

Scientists uncover unknown fail-safe pathway for inherited disorders

Scientists at the University of California, San Diego School of Medicine have uncovered a previously unknown fail-safe (compensatory) pathway that potentially protects the brain and other organs from genetic and environmental threats.

16 Sep 2011

Azithromycin gel may treat borreliosis in humans

Blood-sucking ticks are not just a nuisance, they can also transmit dangerous diseases. One of them is Lyme disease, which is caused by bacteria of the genus Borrelia, and requires a course of treatment with antibiotics lasting several weeks. LMU researchers have come up with a quicker alternative.

16 Sep 2011

Diclofenac in nano-formulated doses provides effective pain relief

A novel formulation of diclofenac provides pain relief at lower-than-standard doses during a Phase II clinical study as reported today at the 2011 World Congress on Osteoarthritis.

16 Sep 2011

Hypnosis to tackle problems of chronic pain: International expert

A visiting international rehabilitation expert has called for Hypnotic Therapy to be considered a ‘mainstream’ treatment option in the management of chronic pain, potentially benefiting thousands of Australian pain sufferers.

15 Sep 2011

International patient groups anxiously await start of Huntington’s trial

Prana Biotechnology Limited received a very positive reaction from international patient groups and researchers at this week’s World Congress on Huntington’s Disease in Melbourne. The company had a major presence at the Congress and the Prana team has held numerous meetings and conversations with patient groups and researchers.

15 Sep 2011

Cempra's solithromycin demonstrates efficacy comparable to levofloxacin for CABP treatment

Cempra Pharmaceuticals today announced results from its Phase II clinical trial investigating the efficacy, safety and tolerability of oral administration of our fourth generation macrolide, solithromycin (CEM-101), a fluoroketolide antibiotic, in comparison with oral levofloxacin for the treatment of community-acquired bacterial pneumonia (CABP).

15 Sep 2011

ODAC recommends ApoPharma's Ferriprox for FDA approval to treat transfusional iron overload

ApoPharma Inc. today announced that the Oncologic Drugs Advisory Committee (ODAC) to the U.S. Food and Drug Administration (FDA) voted 10 - 2 to recommend that the FDA grant accelerated approval of Ferriprox (deferiprone), an oral iron chelator, for the treatment of patients with transfusional iron overload when current chelation therapy is inadequate.

15 Sep 2011

First effective blood-stage vaccine against malaria

Scientists have identified the first effective blood-stage malaria vaccine, according to a New England Journal of Medicine study from University of Maryland School of Medicine researchers, in collaboration with the University of Bamako in Mali, West Africa, and other partners.

15 Sep 2011

SARcode Bioscience initiates enrollment in SAR 1118 Phase 3 study for dry eye disease

SARcode Bioscience, Inc., a privately-held biopharmaceutical company, announced today that the initial patient has been enrolled in the company's pivotal Phase 3 clinical study (OPUS-1) of SAR 1118 ophthalmic solution.

15 Sep 2011

Enrollment commences in ConjuChem's CJC-1134-PC Phase 2 trial for Type 2 diabetes

ConjuChem, LLC, a biotechnology company dedicated to the discovery of novel therapeutics, today announced it has initiated patient enrollment for its Phase 2 clinical trial of its proprietary GLP-1 receptor agonist drug, CJC-1134-PC, in patients with Type 2 diabetes mellitus who are receiving metformin monotherapy.

15 Sep 2011

New Zealand biotechnology company moves to US

Today leading New Zealand biotechnology company Therapy Cell Ltd announced it was moving to the United States through its merger with Therapy Cells Inc (formerly DIII OTC Market). This exciting Bio Tech/Med tech Company holds the exclusive technology that allows adult cells from a specific tissue (e.g. Achilles tendon) to grow again from an individual to enact repair and regeneration of that tissue.

14 Sep 2011

Researchers may have solved 100-year-old puzzle to safely open and close the blood-brain barrier

Cornell University researchers may have solved a 100-year puzzle: How to safely open and close the blood-brain barrier so that therapies to treat Alzheimer's disease, multiple sclerosis and cancers of the central nervous system might effectively be delivered.

14 Sep 2011

FDA grants Orphan Drug Designation for Accentia's Revimmune to prevent GVHD

Accentia Biopharmaceuticals, Inc. and its majority-owned subsidiary, Biovest International, Inc., today jointly announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Revimmune, the Company's proprietary system-of-care based on high-dose administration of Cytoxan, for the prevention of graft-versus-host disease (GVHD) following bone marrow transplant.

14 Sep 2011

Positive data from Aeterna Zentaris' AEZS-108 Phase 2 study on advanced endometrial cancer

Aeterna Zentaris Inc. earlier today, presented positive final Phase 2 efficacy and safety data for its targeted cytotoxic luteinizing hormone releasing hormone (LHRH) analog, AEZS-108, in advanced endometrial cancer.

14 Sep 2011

New data from Pfizer's investigational oncology compounds to be presented at EMCC 2011

Pfizer Oncology announced today that data evaluating crizotinib in anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC), as well as data from Pfizer's renal cell carcinoma (RCC) portfolio on axitinib, an investigational compound, and SUTENT(sunitinib malate) will be presented at the 2011 European Multidisciplinary Cancer Congress in Stockholm, Sweden, September 23 - 27, 2011.

14 Sep 2011

Efficacy News and Research

Experimental malaria vaccine shows positive results among children in small Burkina Faso study

Scientists uncover unknown fail-safe pathway for inherited disorders

Azithromycin gel may treat borreliosis in humans

Diclofenac in nano-formulated doses provides effective pain relief

Hypnosis to tackle problems of chronic pain: International expert

International patient groups anxiously await start of Huntington’s trial

Cempra's solithromycin demonstrates efficacy comparable to levofloxacin for CABP treatment

ODAC recommends ApoPharma's Ferriprox for FDA approval to treat transfusional iron overload

First effective blood-stage vaccine against malaria

SARcode Bioscience initiates enrollment in SAR 1118 Phase 3 study for dry eye disease

Enrollment commences in ConjuChem's CJC-1134-PC Phase 2 trial for Type 2 diabetes

New Zealand biotechnology company moves to US

Researchers may have solved 100-year-old puzzle to safely open and close the blood-brain barrier

FDA grants Orphan Drug Designation for Accentia's Revimmune to prevent GVHD

Positive data from Aeterna Zentaris' AEZS-108 Phase 2 study on advanced endometrial cancer

New data from Pfizer's investigational oncology compounds to be presented at EMCC 2011

Merck issues statement on GARDASIL human papillomavirus vaccine

Nanobiotix starts clinical trial of new cancer treatment for soft tissue sarcoma

VIVUS presents positive results from avanafil phase 3 study in diabetics at 47th EASD meeting

AM-Pharma announces €29.2m series D round of financing

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News